½ðºÌÓéÀÖ³Ç

Brussels (Belgium), 8 July 2022 ¨C 20:00 (CEST) ¨C Regulated information 

Acquisition of own shares

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, ½ðºÌÓéÀÖ³Ç SA/NV (¡°½ðºÌÓéÀֳǡ± or the ¡°Company) (Euronext Brussels: ½ðºÌÓéÀÖ³Ç) hereby discloses certain information in relation to its Share Repurchase Program 2022. 

Under this program, ½ðºÌÓéÀÖ³Ç has requested a financial intermediary to repurchase up to 500 000 ½ðºÌÓéÀÖ³Ç shares on its behalf under the terms of a discretionary mandate agreement with initial validity until 31 August 2022, effective as from 28 June 2022, to cover current and future obligations under ½ðºÌÓéÀÖ³Ç's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2022, ½ðºÌÓéÀÖ³Ç repurchased 145.276 ½ðºÌÓéÀÖ³Ç shares on Euronext Brussels in the period from 1 July 2022 up to and including 7 July 2022, as follows: 

For consistency reasons, ½ðºÌÓéÀÖ³Ç confirms that during the same period, it has not disposed of any ½ðºÌÓéÀÖ³Ç shares within the framework of the Long-Term Incentive Program of the ½ðºÌÓéÀÖ³Ç Group.

This press release is available on ½ðºÌÓéÀÖ³Ç SA/NV¡¯s website via the following link.

For further information, contact ½ðºÌÓéÀÖ³Ç: 

Investor Relations
Antje Witte 
T +32 2 559 94 14
antje.witte@ucb.com

Corporate Communications
Laurent Schots 
T+32 2 559 92 64
laurent.schots@ucb.com     

About ½ðºÌÓéÀÖ³Ç
½ðºÌÓéÀÖ³Ç, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. ½ðºÌÓéÀÖ³Ç is listed on Euronext Brussels (symbol: ½ðºÌÓéÀÖ³Ç). Follow us on Twitter: @½ðºÌÓéÀÖ³Ç_news